🟢 Vivani Medical is trading 5% up today after completing dosing for all 20 SLIM-1 participants

Vivani Medical is trading 5.15% up now at $1.43 after announcing on August 6, 2026, that all 20 participants had been dosed in its SLIM-1 Phase 1 trial of NPM-139, a long-acting semaglutide implant; the milestone appears to be the move’s strongest company-specific catalyst.

• NPM-139 is being evaluated as a six- to twelve-month semaglutide implant.
• Top-line trial data is expected in November 2026.
• Biotech-sector strength and broader risk-on sentiment may provide additional support.